During the corresponding time, Geron Corporation recorded a revenue increase by 30.89 % year on year, sequentially revenue grew by 8.54 %. While revenue at the Geron Corporation's corporate clients
The company serves patients prescribed RYTELO, including those eligible for the REACH4RYTELO patient support program. Its target patient population consists of adults with transfusion-dependent anemia due to lower-risk myelodysplastic syndromes (MDS). The company plans to commercialize RYTELO in select European Union markets in 2026 through partnerships with experienced third parties. Outside the United States, patient access is facilitated via Named Patient Programs (NPPs) in collaboration with Tanner Pharma, a global distributor. The company's customer-facing teams comprise over 60 professionals, including key account managers, regional business directors, regional marketers, regional access directors, and regional medical scientific directors.
Recent notices issued by The Gross Law Firm and Levi and Korsinsky, LLP indicate that Geron Corporation (NASDAQ: GERN), a company specialized in developing therapies for cancer treatment, finds itself embroiled in class action lawsuits. These developments, which emerged starting mid-April 2025, signal a tumultuous period for the company that could have lasting implications for its shareholders, reputation, and future prospects. This article examines the circumstances surrounding these lawsuits and evaluates their potential impacts on Geron Corporation. Background of the Case The Gross Law Firm announced a class action lawsuit against Geron Corporation with a deadline for shareholders to join by May 12, 2025...
In recent developments, Geron Corporation (NASDAQ: GERN) has caught the attention of investors and legal analysts alike due to a notice issued by The Gross Law Firm, urging shareholders to contact them before May 12, 2025. This action raises several questions about the implications for shareholders and the broader impact on the company. This article aims to outline the key facts presented in the legal notice and assess their significance both for Geron Corporation and its shareholders. Key Facts 1. Legal Notice Issuance : The Gross Law Firm has issued a notice to shareholders of Geron Corporation, suggesting that investors might have legal rights to consider. The firm is advocating for those who may have su...
In a significant development within the biotech sector, Geron Corporation, a noted leader in the development of therapies for hematologic malignancies, has recently become the focal point of a class action lawsuit. On April 15, 2025, The Gross Law Firm announced the filing of this lawsuit aimed at seeking financial recovery for shareholders who have allegedly suffered losses due to the company s actions. This legal motion comes amid increasing scrutiny of corporate governance practices and transparency in the pharmaceutical industry. The Allegations Against Geron Corporation Publicly listed on the NASDAQ under the ticker GERN, Geron Corporation has faced growing challenges stemming from accusations related t...
In a significant boost for both Geron Corporation and patients suffering from lower-risk myelodysplastic syndromes (MDS), the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has delivered a positive opinion for RYTELO (imetelstat). This recommendation paves the way for the potential approval of RYTELO as a treatment for adults experiencing transfusion-dependent anemia, specifically in cases of very low, low, or intermediate-risk MDS. Key Facts1. Breakthrough Treatment : RYTELO is aimed at patients grappling with transfusion-dependent anemia a condition wherein patients require regular blood transfusions to manage their symptoms. This typically arises due to under...
: Geron Corporation, a Nasdaq-listed commercial-stage biopharmaceutical company, recently announced the release of several abstracts highlighting new findings related to RYTELO (imetelstat), a pioneering telomerase inhibitor, in the treatment of myeloid hematologic malignancies. These findings are scheduled to be presented during the 66th American Society of Hematology (ASH) Annual Meeting, underscoring the company s ongoing commitment to advancing therapies that could revolutionize the management of blood cancers.Telomerase inhibitors represent a novel therapeutic approach in oncology, targeting the maintenance of telomeres that facilitates the unlimited proliferative capacity of cancer cells. Geron Corpora...
Groundbreaking Developments: NCCN Guidelines Update and FDA Approval Endorse RYTELO (Imetelstat) for Treatment of Symptomatic Anemia in Lower-Risk MDS Patients FOSTER CITY, Calif. - Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical pioneer dedicated to transforming lives by altering the trajectory of blood cancer, proudly announced two significant advancements in the therapeutic landscape for Myelodysplastic Syndromes (MDS). In a critical update, the National Comprehensive Cancer Network (NCCN) has revised its Clinical Practice Guidelines in Oncology (NCCN Guidelines) to include RYTELO (imetelstat) as a Category 1 and 2A recommendation for the treatment of symptomatic anemia in patient...
Foster City, CA based Geron Corporation (Nasdaq: GERN), a leading company at the forefront of biopharmaceutical research and late-clinical-stage developments, has released its financial results and business highlights for the first quarter of 2024. The company, specializing in the path-breaking development of imetelstat, the first-in-class investigational telomerase inhibitor utilized in the treatment of specific malignant blood disorders, has recently witnessed a significant boost in its industry stature.Geron made advancements in the first quarter, marked most notably by the FDA’s Oncologic Drugs Advisory Committee (ODAC) delivering a 12 to 2 vote endorsing the clinical benefit/risk profile of imetelstat...
Geron’s Comment on Sales, Marketing and Customers
The company serves patients prescribed RYTELO, including those eligible for the REACH4RYTELO patient support program. Its target patient population consists of adults with transfusion-dependent anemia due to lower-risk myelodysplastic syndromes (MDS). The company plans to commercialize RYTELO in select European Union markets in 2026 through partnerships with experienced third parties. Outside the United States, patient access is facilitated via Named Patient Programs (NPPs) in collaboration with Tanner Pharma, a global distributor. The company's customer-facing teams comprise over 60 professionals, including key account managers, regional business directors, regional marketers, regional access directors, and regional medical scientific directors.
Sources:
Geron Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Geron Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Geron Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
190.06 %